: iStockAnalyst.com Symbols Feed

11 Hot Stocks To Short & Mark Cuban Getting Caught For Insider Trading On Copernic Inc. (CNIC)

Mon, 17 Nov 2008 17:24:00 GMT

NEWSFLASH: WSJ Reporting Mark Cuban gets charged with insider trading on Mamma.com, now Copernic Inc. (CNIC) Hahaha, this is my territory with the sketchy PIPEs and volatile stocks–anybody... Visit TimothySykes.com to read full article with comments [More...]

Starting To Get Worried But Not Really

Fri, 22 Aug 2008 14:17:00 GMT

I hope that my internal feelings are a contrarian but as every day that goes along that I continue to scan my charts and see nothing that looks like it wants to rally or make higher highs in a proper fashion I get a little more nervous that I begin to think that this bear market is going to go on a lot longer than I would like it to. I am not sure where I heard the saying, or if I even ever heard the saying and have come up with it on my own by studying the market, but if a bear market does not last six months or less it usually last two years or longer. The problem now is the it is clearly past six months since the top in November but at the same time there are absolutely zero charts that are ought there with beautiful patterns that make me feel comfortable that we have a real rally coming along any time soon. Instead what I see are ugly rallies in medical and other defensive stocks that do not give investors a safe chance to get in or[More...]

Stocks Put In Weak Gains On Even Weaker Volume

Thu, 21 Aug 2008 14:21:00 GMT

When it comes to making a living in the stock market I have had no problem doing that for the past thriteen years. But all of a sudden this year, this trendless market has made it near impossible to make a lot of money. There are a few mutual funds that are up for the year but the majority of the greatest funds and greatest traders are finding it very difficult to make money in a market that simply does not go anywhere.Now, while we have had some big winners like PDO, XCO, and DGLY, we have also had some disappointments like BRKR BKE and AEHR. If this would have been a start of a bull market, like 2003 was, after the 2000-2002 downtrend, I am sure they would have all worked but for right now things still rarely work. But it is obviously clear to me that this market is not moving up or down and that it is just going nowhere. Why then, in God’s name, why would you be wanting to be going long or short stocks. It is clear from where I sit[More...]

Analyst Comments: Optimer Pharma, CREE, Delphi Financial, VeraSun, InterDigital, Greenfield Online

Thu, 14 Aug 2008 05:05:00 GMT

Optimer Pharmaceuticals, Inc. (OPTR) is a biopharmaceutical company specializing in anti-infective drug development and commercialization.[More...]

Periodicals Wrap-Up for Wednesday, August 13th

Wed, 13 Aug 2008 14:01:00 GMT

Posted By Optiondragon for myhappytrading.com[More...]

Analyst Comments: Net Servicos, Highwoods, Gushan Environmental Energy, Accuray, Optimer Pharmaceuticals

Wed, 09 Jul 2008 19:22:00 GMT

We are reiterating our Buy recommendation on Net Servicos (NETC). Although higher worldwide inflation and interest rates, particularly in Brazil, are source of great concern, we are highly encouraged by the company's solid operating results during the first quarter. We expect this trend to continue in the short term due to the still positive economic environment in Brazil. Brazil was...[More...]

Analyst Comments: VeriSign, Metabolix, Cabot Oil, Optimum, American Axle, Superior Industries

Tue, 13 May 2008 03:10:53 GMT

VeriSign (VRSN) reported revenue of $223 million, up 23% year-over-year [y/y]. Stronger-than-expected EBIT margins of 30.3% were mitigated by higher net interest expense (lower rates, less cash). Second quarter 2008 guidance called for revenue of $228-$23[More...]

Analyst Comments: Banco de Chile, American Axle, Optimer Pharmaceuticals, Boston Properties, Kimberly-Clark, PartnerRe

Fri, 28 Mar 2008 16:02:50 GMT

We are maintaining our Hold on Banco de Chile (BCH), but raising our target price to $52. BCH posted fourth quarter net earnings of Ch$78,715 million, up 86% year-over-year. We expect Banco de Chile's strong results over the past few years to moderate. Specifically, we expect gains in the efficiency ratio to slow from its past torrid pace, and outsized increases in non-interest income to diminish. As a result, we believe that EPS growth over the next few years...[More...]

Analyst Comments: Morton's Restaurants, Southern Copper's, PMI Group, Jamba Juice, Lockheed Martin, Dynamic Materials, Centennial Communications, Celanese, Equinix, Optimer Pharmaceuticals

Thu, 10 Jan 2008 05:12:14 GMT

Zacks senior restaurant industry analyst Ann Northrop, CFA downgraded shares of Morton's Restaurants (MRT) from Buy to Hold a month ago. She currently is reiterating her recommendation on shares of the upscale steakhouse chain:'Morton's reputation for serving world-class food and hospitality is driving strong sales, which, coupled with its stringent cost management,...[More...]

Optimer Posts Loss

Wed, 11 Mar 2009 18:47:59 GMT

California-based biopharmaceutical company Optimer Pharmaceuticals has reported net loss of $10.4 million, or $0.35 per common share for the fourth quarter of 2008 compared to a net loss of $7 million, or $0.27 per common share for the same period of 2007.[More...]

Optimer to Secure $32.9 Million in Registered Direct Offering

Fri, 06 Mar 2009 14:50:00 GMT

Optimer Pharmaceuticals, a biopharmaceutical company, has received commitments from institutional investors to purchase approximately $32.9 million of its securities pursuant to an effective shelf registration statement.
Under the terms of one of two types of purchase agreements, Optimer will sell 2.79 million newly issued shares of its common stock at a purchase price of $10 per share.
In the other purchase agreement Optimer will sell 457,666 newly issued units at a purchase price of $10.925 per unit, with each unit consisting of one share of common stock and one warrant to purchase 0.20 of a share of common stock.

[More...]

Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results

Wed, 05 Aug 2009 11:56:00 GMT

Optimer Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2009. Optimer reported a net loss for the second quarter of 2009 of $12.4 million, or $0.37 per share, which was in line with the Company's expectations. This compares to a net loss for the second quarter of 2008 of $8.1 million, or $0.29 per share. The increase in net loss was primarily due to higher research and development expenses. Research and development expenses in the second quarter of 2009 were $10.5 million, compared to $6.2 million in the second quarter of 2008. The increase was primarily due to manufacturing scale-up expenses and expenses to prepare regulatory filings related to the Company's fidaxomicin and prulifloxacin programs.[More...]

Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference

Tue, 04 Aug 2009 11:56:00 GMT

Optimer Pharmaceuticals, Inc. is scheduled to present at the Canaccord Adams 29th Annual Global Growth Conference at the Intercontinental Hotel in Boston on August 13, 2009, 2:00 p.m. Eastern Time.[More...]

Optimer Pharmaceuticals to Present at June 2009 Investor Conferences

Thu, 04 Jun 2009 11:57:00 GMT

Optimer Pharmaceuticals, Inc. today announced that the Company will present at the following investor conferences:[More...]

Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI

Tue, 02 Jun 2009 19:30:00 GMT

Optimer Pharmaceuticals, Inc. announced that additional results from its North American Phase 3 clinical study of fidaxomicin in patients with Clostridium difficile infection were presented today by clinical investigator, Mark A. Miller, M.D., at the Digestive Disease Week 2009 conference in Chicago.[More...]

Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection

Sun, 17 May 2009 07:25:00 GMT

Positive data from subgroup analysis presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases meeting in Helsinki, Finland[More...]

Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results

Thu, 07 May 2009 11:57:00 GMT

Optimer Pharmaceuticals, Inc. today announced its financial results for the first quarter ended March 31, 2009. Optimer reported a net loss for the first quarter of 2009 of $10.9 million, or $0.36 per share which was in line with the Company's expectations. This compares to a net loss for the first quarter of 2008 of $7.9 million, or $0.28 per share. Research and development expenses in the first quarter of 2009 were $8.8 million compared to $6.9 million in the first quarter of 2008. The increase is primarily due to an increase in clinical development and regulatory expenses related to Optimer's fidaxomicin and prulifloxacin programs.[More...]

Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin

Mon, 13 Apr 2009 13:49:00 GMT

SAN DIEGO, April 13 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced today that the United States Patent and Trademark Office issued a production patent (U.S. Patent No.
7,507,564) covering steps used in the manufacture of fidaxomicin, which is currently in its second Phase 3 clinical trial for the treatment of Clostridium difficile infection, or CDI.
"The issuance of this production patent is another important milestone in strengthening the patent estate of our lead product candidate, fidaxomicin," said Michael N. Chang, Ph.D., President and CEO of Optimer.

[More...]

Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Financial Results

Wed, 11 Mar 2009 18:32:00 GMT

Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) today announced 2008 fourth quarter and full year financial results and accomplishments.[More...]

Optimer Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference

Mon, 09 Mar 2009 11:59:00 GMT

Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) is scheduled to present at the Cowen and Company 29th Annual Health Care Conference at The Boston Marriott Copley Place on March 17, 2009, 1:40 p.m. Eastern Time.[More...]

Optimer Pharmaceuticals to Raise $32.9 Million in Registered Direct Offering

Thu, 05 Mar 2009 12:01:00 GMT

Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that it has received commitments from institutional investors to purchase approximately $32.9 million of its securities pursuant to an effective shelf registration statement.[More...]